Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

18.48 -0.63 (-3.30%)
Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 Next >
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
From Novocure
Via Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
From Novocure
Via Business Wire
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
From Novocure
Via Business Wire
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
From Novocure
Via Business Wire
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
From Novocure
Via Business Wire
NovoCure Limited (NASDAQ:NVCR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- An investigation was announced for investors in shares of NovoCure Limited (NASDAQ:NVCR) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
Novocure to Report Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
From Novocure
Via Business Wire
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
From Novocure
Via Business Wire
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
From Novocure
Via Business Wire
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.